SCHEMBL19900082

SCHEMBL19900082

c1cc(NC2CNC2)nc(-c2cnc3ccccn23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 1.00
IRAK4 Q9NWZ3 11/20 1.00
NRAS P01111 4/20 0.70
IRAK1 P51617 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22145801 0.91 IRAK4 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL22145804 0.89 IRAK4 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL18427792 0.88 IRAK4 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL24606332 0.86 IRAK4 (0.80) FLT3IRAK4IRAK1
SCHEMBL24231229 0.86 IRAK4 (0.76) FLT3IRAK4NRAS
SCHEMBL25989914 0.86 IRAK4 (0.76) FLT3IRAK4NRAS
SCHEMBL19900089 0.84 FLT3 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL19900057 0.84 FLT3 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL19918141 0.82 FLT3 (1.00) FLT3IRAK4NRASIRAK1
SCHEMBL19900090 0.82 FLT3 (1.00) FLT3IRAK4NRASIRAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542261-B2 Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-01-03 US disclosed
US-11542261-B2 Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-01-03 US disclosed
US-20220306621-A9 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINES AS IRAK 1/4 AND FLT3 INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-09-29 US disclosed
US-20220235042-A1 Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER 2022-07-28 US disclosed
US-20220213094-A1 Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-07-07 US disclosed
US-20220213094-A1 Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-07-07 US disclosed
US-11254667-B2 Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-02-22 US disclosed
US-11254667-B2 Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-02-22 US disclosed
EP-3854796-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM Children's Hospital Medical Center (US) 2021-07-28 EP disclosed
EP-3854796-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM Children's Hospital Medical Center (US) 2021-07-28 EP disclosed
EP-3500571-B1 IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM CHILDRENS HOSPITAL MED CT (US) 2020-12-30 EP disclosed
EP-3500571-B1 IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM CHILDRENS HOSPITAL MED CT (US) 2020-12-30 EP disclosed
US-20200270242-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2020-08-27 US disclosed
US-20200270242-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2020-08-27 US disclosed
US-20200199123-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS CHILDRENS HOSPITAL MED CT (US) 2020-06-25 US disclosed
US-20200199123-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS CHILDRENS HOSPITAL MED CT (US) 2020-06-25 US disclosed
EP-3500571-A2 IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM Children's Hospital Medical Center (US) 2019-06-26 EP disclosed
WO-2018038988-A2 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2018-03-01 WO disclosed
WO-2018038988-A2 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199123-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS IRAK1, IRAK2, IRAK3 FLT3 63/4885IRAK4 4/4885NRAS 236/4885
US-20220235042-A1 Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors IRAK1, IRAK4, IRAK2 FLT3 5/4885IRAK4 2/4885NRAS 239/4885
US-11254667-B2 Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors IRAK1, IRAK4, FLT3 FLT3 3/4885IRAK4 2/4885NRAS 121/4885
US-20220213094-A1 Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors IRAK1, IRAK4, FLT3 FLT3 3/4885IRAK4 2/4885NRAS 124/4885
US-20220306621-A9 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINES AS IRAK 1/4 AND FLT3 INHIBITORS IRAK1, IRAK4, IRAK2 FLT3 5/4885IRAK4 2/4885NRAS 185/4885
US-20200270242-A1 COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS VHL, ETV6, C5 FLT3 549/4885IRAK4 1906/4885NRAS 41/4885
US-11542261-B2 Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors IRAK1, IRAK4, IRAK2 FLT3 5/4885IRAK4 2/4885NRAS 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.